TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 976301

Group type: EXPERIMENTAL
Intervention: Isoproterenol (beta-adrenergic receptor stimulatory agent)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beef meal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Isoproterenol and beef meal combined
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propranolol (beta-adrenergic receptor blocking agent)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Basal serum gastrin concentrations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Isoproterenol and meal stimulated gastrin secretion
Number of subjects: 0
Study: 31995619

Group type: EXPERIMENTAL
Intervention: Pembrolizumab combination therapy
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Pembrolizumab monotherapy
Number of subjects: 3

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 3
Study: 31037724

Group type: EXPERIMENTAL
Intervention: Needle tip tracking (NTT) for out-of-plane procedures
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Needle tip tracking (NTT)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Needle tip tracking (NTT) for in-plane procedures
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (without NTT) for in-plane procedures
Number of subjects: 40
Study: 28282523

Group type: EXPERIMENTAL
Intervention: Adolescent Community Reinforcement Approach (A‐CRA)
Number of subjects: 1712
Study: 26940721

Group type: EXPERIMENTAL
Intervention: Capitated global budget and pay-for-performance (CGB + P4P)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Capitated global budget (CGB)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Both groups (CGB and CGB + P4P)
Number of subjects: 0
Study: 25124565

Group type: EXPERIMENTAL
Intervention: CIK cell therapy
Number of subjects: 943

Group type: COMPARATOR
Intervention: Conventional therapy (Control)
Number of subjects: 943
Study: 21812536

Group type: EXPERIMENTAL
Intervention: Single intravenous dose of CpG 7909 (1.05 mg/kg)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Single subcutaneous dose of CpG 7909 (0.45 mg/kg)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Multiple weekly subcutaneous doses of CpG 7909 (0.45 mg/kg)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: CpG 7909 administration
Number of subjects: 41
Study: 19294955

Group type: EXPERIMENTAL
Intervention: Ramelteon, 8 mg nightly for 6 months
Number of subjects: 451

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 451
Study: 17465861

Group type: EXPERIMENTAL
Intervention: Lidocaine (needle-free injection)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo (isotonic saline)
Number of subjects: 107
Study: 16083602

Group type: EXPERIMENTAL
Intervention: External vavuloplasty of the superficial femoral vein and surgery of superficial venous system (group A)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Surgery of superficial venous system only (group B)
Number of subjects: 30
Study: 14727250

Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy (IMRT)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Concomitant chemotherapy and IMRT with subcutaneous amifostine (Ethyol, WR-2721)
Number of subjects: 126
Study: 10225080

Group type: EXPERIMENTAL
Intervention: Leucocyte depleting arterial line filter (LG‐6 group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard arterial line filter (AV‐6 group)
Number of subjects: 40
Study: 8561317

Group type: EXPERIMENTAL
Intervention: Clonidine 4 micrograms/kg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Clonidine 2 micrograms/kg
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 1901076

Group type: EXPERIMENTAL
Intervention: Intravenous recombinant tissue‐type plasminogen activator (rtPA) 100 mg
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 6752448

Group type: COMPARATOR
Intervention: C 50+R 0.25
Number of subjects: 329

Group type: COMPARATOR
Intervention: C 50+R 0.125
Number of subjects: 329

Group type: COMPARATOR
Intervention: C 50+R 0.05
Number of subjects: 329

Group type: COMPARATOR
Intervention: C 25+R 0.125
Number of subjects: 329
Study: 31989690

Group type: EXPERIMENTAL
Intervention: basic vision rehabilitation service (basic-VRS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: usual low vision care
Number of subjects: 0
Study: 31348731

Group type: EXPERIMENTAL
Intervention: 1 dose of MenAC-TT vaccine
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: 2 doses of MenAC-TT vaccine
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Both 1 and 2 doses of MenAC-TT vaccine
Number of subjects: 301
Study: 28376919

Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitization and Reprocessing (EMDR) therapy
Number of subjects: 82

Group type: COMPARATOR
Intervention: Supportive therapy
Number of subjects: 82
Study: 27137661

Group type: EXPERIMENTAL
Intervention: Safety Workshop (SW)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Online Curriculum (OC)
Number of subjects: 51
Study: 24418178

Group type: EXPERIMENTAL
Intervention: Computer-assisted orthognathic corrective surgery
Number of subjects: 20

Group type: COMPARATOR
Intervention: Classic orthognathic corrective surgery
Number of subjects: 20
Study: 22405221

Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT)
Number of subjects: 289

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 289
Study: 19190912

Group type: EXPERIMENTAL
Intervention: Urokinase instillation (thrice daily)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Saline irrigation alone
Number of subjects: 100
Study: 17552960

Group type: EXPERIMENTAL
Intervention: Sildenafil (25, 50 or 100 mg)
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: Tadalafil (10 or 20 mg)
Number of subjects: 367

Group type: COMPARATOR
Intervention: Sildenafil or Tadalafil
Number of subjects: 367
Study: 16109114

Group type: EXPERIMENTAL
Intervention: Buspirone (10 mg/day) for 6 weeks
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo for 6 weeks
Number of subjects: 74
Study: 12454450

Group type: EXPERIMENTAL
Intervention: Participatory education group
Number of subjects: 102

Group type: COMPARATOR
Intervention: Traditional education group
Number of subjects: 102
Study: 9536583

Group type: EXPERIMENTAL
Intervention: Inhaler devices (Accuhaler, Autohaler, Turbohaler, Diskhaler)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Metered dose inhaler and Accuhaler
Number of subjects: 20
Study: 7971707

Group type: EXPERIMENTAL
Intervention: Sodium lauryl sulphate (SLS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Polyoxyethylene 20 sorbitan monooleate (Tween)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cetyltrimethylammonium bromide (CTAB)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral solution of felodipine
Number of subjects: 0
Study: 3661282

Group type: EXPERIMENTAL
Intervention: Impersonal recruitment (letters sent by employee mail)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Interpersonal recruitment (personal phone calls)
Number of subjects: 119
Study: 30697471

Group type: EXPERIMENTAL
Intervention: Financial incentives up to $320/year
Number of subjects: 2003
Study: 30081574

Group type: EXPERIMENTAL
Intervention: Stringent group (S-group) with three meal replacements/day
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Moderate group (M-group) with two meal replacements/day
Number of subjects: 321

Group type: COMPARATOR
Intervention: Observational control group with routine care
Number of subjects: 321
Study: 27042258

Group type: EXPERIMENTAL
Intervention: Magnesium supplementation for four weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (nonsupplemented group)
Number of subjects: 0
Study: 25064674

Group type: EXPERIMENTAL
Intervention: Systolic blood pressure visit-to-visit variability
Number of subjects: 2739
Study: 22863216

Group type: EXPERIMENTAL
Intervention: IL18 rs360719 CC genotype
Number of subjects: 518

Group type: EXPERIMENTAL
Intervention: IL18 rs360719 CC combined with IL12A rs568408 GG
Number of subjects: 518

Group type: EXPERIMENTAL
Intervention: IL18 rs360719 CC combined with IL12A rs568408 GA
Number of subjects: 518

Group type: EXPERIMENTAL
Intervention: IL18 rs360719 CC combined with IL12A rs568408 GG/AA
Number of subjects: 518

Group type: EXPERIMENTAL
Intervention: IL12B rs3212227 AA combined with IL18 rs360719 CC
Number of subjects: 518

Group type: EXPERIMENTAL
Intervention: rs568408 AA and rs360719 TT genotypes
Number of subjects: 518

Group type: EXPERIMENTAL
Intervention: rs568408 GG and rs360719 TT genotypes
Number of subjects: 518

Group type: EXPERIMENTAL
Intervention: rs3212227 CC and rs360719 TC genotypes
Number of subjects: 518
Study: 19604407

Group type: EXPERIMENTAL
Intervention: Paleolithic diet
Number of subjects: 13
Study: 17805239

Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 14681845

Group type: EXPERIMENTAL
Intervention: Stevioside (1 g)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Maize starch (1 g)
Number of subjects: 12
Study: 11642632

Group type: EXPERIMENTAL
Intervention: DTaP‐HB‐IPV
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: DTaP‐HB‐IPV at 2 and 4 months, DTaP‐HB with OPV at 6 months
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: DTaP‐HB with licensed IPV (IPOL) administered separately
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Separate doses of OPV, DTaP, and HB
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: New IPV
Number of subjects: 400
Study: 9494004

Group type: EXPERIMENTAL
Intervention: Early feeding group (free fluids from 4 hours postoperatively, solid diet from first postoperative day as tolerated)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (nil orally until passage of flatus or bowel motion, then fluids progressing to solids over 24-48 hours)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Early feeding group
Number of subjects: 80
Study: 8311205

Group type: EXPERIMENTAL
Intervention: Epidural bupivacaine infusion at 7 ml.h‐1 of a 0.25% solution
Number of subjects: 20

Group type: COMPARATOR
Intervention: Epidural bupivacaine infusion at 25 ml.h‐1 of a 0.07% solution
Number of subjects: 20
Study: 3230909

Group type: EXPERIMENTAL
Intervention: Interval dance group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continuous dance group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 8252509

Group type: EXPERIMENTAL
Intervention: Buserelin and flutamide
Number of subjects: 122

Group type: COMPARATOR
Intervention: Buserelin alone
Number of subjects: 122
Study: 343727

Group type: EXPERIMENTAL
Intervention: naproxen (500-750 mg daily)
Number of subjects: 20

Group type: COMPARATOR
Intervention: phenylbutazone (400-600 mg daily)
Number of subjects: 20

Group type: COMPARATOR
Intervention: phenylbutazone
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: naproxen
Number of subjects: 20
Study: 31858245

Group type: EXPERIMENTAL
Intervention: UDCA (Ursodeoxycholic acid)
Number of subjects: 1432

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1432

Group type: EXPERIMENTAL
Intervention: SG (Sleeve Gastrectomy)
Number of subjects: 1432

Group type: EXPERIMENTAL
Intervention: OAGB (One Anastomosis Gastric Bypass)
Number of subjects: 1432

Group type: EXPERIMENTAL
Intervention: GCP (Greater Curve Plication)
Number of subjects: 1432
Study: 31615796

Group type: EXPERIMENTAL
Intervention: Online self-care interventions (various types)
Number of subjects: 1060
Study: 28863914

Group type: EXPERIMENTAL
Intervention: Skeletally anchored facemasks with miniplates at the zygomatic buttress (Group 1)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Class III elastics from infrazygomatic miniplates in the maxilla to symphyseal miniplates in the mandible (Group 2)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Untreated control group (Group 3)
Number of subjects: 30
Study: 26051572

Group type: EXPERIMENTAL
Intervention: PC 6 acupoint stimulation via beaded intervention wristbands
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo sham wristband
Number of subjects: 80
Study: 22743782

Group type: EXPERIMENTAL
Intervention: Atrial fibrillation (AF) patients with ST elevation AMI and single vessel disease
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (sinus rhythm patients with AMI and single vessel disease)
Number of subjects: 14
Study: 20737495

Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg/2 mL IV
Number of subjects: 102

Group type: COMPARATOR
Intervention: NaCl 0.9% 2 mL IV
Number of subjects: 102
Study: 19634956

Group type: EXPERIMENTAL
Intervention: Iowa Strengthening Families Program (ISFP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Preparing for the Drug Free Years (PDFY)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 16617930

Group type: EXPERIMENTAL
Intervention: HAART (Highly Active Antiretroviral Therapy)
Number of subjects: 0
Study: 15121264

Group type: EXPERIMENTAL
Intervention: Erbium (Er):YAG laser
Number of subjects: 42

Group type: COMPARATOR
Intervention: Surgical bur
Number of subjects: 42
Study: 11333173

Group type: EXPERIMENTAL
Intervention: Flecainide (low-dose oral)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Flecainide
Number of subjects: 5

Group type: COMPARATOR
Intervention: Control (Mexiletine)
Number of subjects: 5
Study: 9386870

Group type: EXPERIMENTAL
Intervention: Single view mammography screening
Number of subjects: 40318

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 40318

Group type: EXPERIMENTAL
Intervention: Single view mammography screening (for women aged 50-64)
Number of subjects: 40318

Group type: EXPERIMENTAL
Intervention: Single view mammography screening (for women aged 40-49)
Number of subjects: 40318
Study: 7952623

Group type: EXPERIMENTAL
Intervention: Salmeterol (42 micrograms)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Albuterol (180 micrograms)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161
Study: 3606918

Group type: EXPERIMENTAL
Intervention: Anaesthesia with isoflurane and nitrous oxide at 1.3 MAC
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Anaesthesia with isoflurane and nitrous oxide at 1.5 MAC
Number of subjects: 14
Study: 30549145

Group type: EXPERIMENTAL
Intervention: Intervention group received five 30- to 60-minute sessions at 2-week intervals by master's-prepared patient educators.
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Experimental group (wives)
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Experimental group (wives on chemotherapy)
Number of subjects: 322

Group type: COMPARATOR
Intervention: Control group received the booklet, 'What's Happening to the Woman I Love?'
Number of subjects: 322
Study: 28521831

Group type: EXPERIMENTAL
Intervention: Exercise referral schemes (ERS) for 16 weeks (32 sessions, 45-60 min per session)
Number of subjects: 1338

Group type: EXPERIMENTAL
Intervention: ERS enhanced by seven sessions of self-management strategies (SMSs) and four telephone prompts
Number of subjects: 1338

Group type: COMPARATOR
Intervention: Control group (general recommendations about physical activity)
Number of subjects: 1338
Study: 25525743

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg/d
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/d
Number of subjects: 26
Study: 23566429

Group type: EXPERIMENTAL
Intervention: State-of-the-art strategy including education, reminders, feedback, and optimising materials and facilities
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Team and leaders-directed strategy including all elements of the state-of-the-art strategy, supplemented with social activities and enhancing leadership
Number of subjects: 0
Study: 21205628

Group type: EXPERIMENTAL
Intervention: i.v. lidocaine (Group L, n=35)
Number of subjects: 70

Group type: COMPARATOR
Intervention: remifentanil by TCI (Group R, n=35)
Number of subjects: 70

Group type: COMPARATOR
Intervention: remifentanil by TCI (Group R)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: i.v. lidocaine (Group L)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 70
Study: 18305999

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 148

Group type: COMPARATOR
Intervention: Non-propofol
Number of subjects: 148

Group type: COMPARATOR
Intervention: Propofol and Non-propofol
Number of subjects: 148
Study: 16533388

Group type: EXPERIMENTAL
Intervention: Heart failure self-management program for patients with low literacy; education on self-care, daily weight measurement, diuretic dose self-adjustment, symptom recognition, picture-based materials, digital scale, scheduled follow-up.
Number of subjects: 123

Group type: COMPARATOR
Intervention: Usual care with a generic heart failure brochure.
Number of subjects: 123
Study: 11784522

Group type: EXPERIMENTAL
Intervention: Irrigated-tip catheter
Number of subjects: 37

Group type: COMPARATOR
Intervention: Standard catheter
Number of subjects: 37
Study: 9920082

Group type: EXPERIMENTAL
Intervention: Low isoflavone diet (64 +/‐ 9.2 mg/day)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: High isoflavone diet (128 +/‐ 16 mg/day)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control diet (10 +/‐ 1.1 mg/day)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Isoflavone consumption
Number of subjects: 14
Study: 7593708

Group type: EXPERIMENTAL
Intervention: Sublingual administration of triazolam (0.25 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oral administration of triazolam (0.25 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Intravenous administration of triazolam (0.25 mg)
Number of subjects: 12
Study: 2256974

Group type: EXPERIMENTAL
Intervention: Oxpentifylline 400 mg three times a day for six months
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Oxpentifylline
Number of subjects: 80
Study: 6247656

Group type: EXPERIMENTAL
Intervention: Carbimazole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methimazole (active metabolite of carbimazole)
Number of subjects: 0
Study: 29343016

Group type: EXPERIMENTAL
Intervention: Fentanyl combined with midazolam
Number of subjects: 132

Group type: COMPARATOR
Intervention: 2% lidocaine
Number of subjects: 132
Study: 27409593

Group type: EXPERIMENTAL
Intervention: AV distraction using videotaped cartoons with eyeglass system (i‐theatre™)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group without distraction (CTR-group)
Number of subjects: 56
Study: 24056528

Group type: EXPERIMENTAL
Intervention: Emixustat (5, 10, 20, 30, or 40 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 23019833

Group type: EXPERIMENTAL
Intervention: Calcium hydroxide base liner (Dycal; Dy)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Self-etching primer (Clearfil SE Bond; CSE)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (sound and carious primary dentin)
Number of subjects: 37
Study: 20459744

Group type: EXPERIMENTAL
Intervention: Standard-dose cyclophosphamide, doxorubicin and fluorouracil (CAF)
Number of subjects: 350
Study: 17651679

Group type: EXPERIMENTAL
Intervention: Bilateral Crystalens IOL
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: ReSTOR multifocal IOL
Number of subjects: 49

Group type: COMPARATOR
Intervention: Crystalens IOL
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Bilateral Crystalens
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Combination of Crystalens and ReSTOR
Number of subjects: 49

Group type: COMPARATOR
Intervention: Bilateral multifocal IOL
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Accommodating and multifocal IOL combinations
Number of subjects: 49
Study: 15716155

Group type: EXPERIMENTAL
Intervention: Levodopa (L-dopa) medication
Number of subjects: 20

Group type: COMPARATOR
Intervention: No medication (off L-dopa)
Number of subjects: 20
Study: 11881867

Group type: COMPARATOR
Intervention: 0.25 ml air injection
Number of subjects: 30

Group type: COMPARATOR
Intervention: 0.5 ml air injection
Number of subjects: 30

Group type: COMPARATOR
Intervention: 1 ml air injection
Number of subjects: 30

Group type: COMPARATOR
Intervention: 2 ml air injection
Number of subjects: 30

Group type: COMPARATOR
Intervention: 3 ml air injection
Number of subjects: 30

Group type: COMPARATOR
Intervention: ≥4 ml air injection
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Inter-observer reliability
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intra-observer reliability
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: False positives
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: False negatives
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Specificity
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Sensitivity
Number of subjects: 30
Study: 10405580

Group type: EXPERIMENTAL
Intervention: CD instrumentation (n = 64)
Number of subjects: 130

Group type: COMPARATOR
Intervention: No instrumentation (n = 66)
Number of subjects: 130
Study: 7585847

Group type: EXPERIMENTAL
Intervention: 200 mg cimetidine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 50 mg ranitidine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 40 mg famotidine
Number of subjects: 0
Study: 2145136

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (54 micrograms)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Metaproterenol sulfate (1.95 mg)
Number of subjects: 32
Study: 7189485

Group type: EXPERIMENTAL
Intervention: 200 mg miconazole once daily for 6 days (A)
Number of subjects: 119

Group type: COMPARATOR
Intervention: 400 mg miconazole once daily for 3 days (B)
Number of subjects: 119
Study: 30817716

Group type: EXPERIMENTAL
Intervention: Foam Rolling (FR)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Static Stretching (SS)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Foam Rolling followed by Static Stretching (FR + SS)
Number of subjects: 44

Group type: COMPARATOR
Intervention: All groups (FR, SS, FR + SS)
Number of subjects: 44
Study: 28290274

Group type: EXPERIMENTAL
Intervention: FDC standard dissolution
Number of subjects: 42

Group type: COMPARATOR
Intervention: Individual tablets
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: FDC standard dissolution with food
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: FDC slow dissolution
Number of subjects: 42